Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy

Gynecologic Oncology

Volumn 79, Issue 2, 2000, Pages 272-280

  Chen, Bing Mae ^a   Chen, Jia Yi ^a,b   Kao, Marine ^a   Lin, Jia Bo ^b   Yu, Mu Hsien ^b   Roffler, Steve R ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Camptothecin; Cervical carcinoma; Chemoradiation; Radiation; Topoisomerase I

Indexed keywords

CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; UTERINE CERVIX CANCER;

EID: 0033762371     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5947     Document Type: Article

References (47)

1. Cancer statistics, 2000
2. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer
3. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma
4. High-dose-rate intracavitary brachytherapy (HDR-IC) in treatment of cervical carcinoma: 5-year results and implication of increased low-grade rectal complication on initiation of an HDR-IC fractionation scheme
5. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study
6. Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma
7. Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience
8. Topotecan in the treatment of gynecologic cancer
9. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix
10. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives
11. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells
12. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin
13. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA
14. A model for tumor cell killing by topoisomerase poisons
15. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA
16. A model for the mechanism of human topoisomerase I
17. Plant antitumor agents. I. The isolation and structure of campthecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
18. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
19. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
20. Potentiation of radioimmunotherapy by inhibition of topoisomerase I
21. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin
22. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody
23. Overexpression of human DNA topoisomerase I in insect cells using a baculovirus vector
24. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs
25. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
26. CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants
27. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy
28. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer
29. Topoisomerase I activity in squamous cell carcinoma of the head and neck
30. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors
31. DNA topoisomerase I - Targeted chemotherapy of human colon cancer in xenografts
32. DNA-topoisomerase I activity and content in epithelial ovarian cancer
33. Determinants of CPT-11 and SN-38 activities in human lung cancer cells
34. Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies
35. Topoisomerase I phosphorylation in vitro and in rapidly growing Novikoff hepatoma cells
36. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C
37. Poly(ADP-ribosylation) of a DNA topoisomerase
38. Modulation of DNA topoisomerase I activity by p53
39. Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors
40. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines
41. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation
42. Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines
43. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880)
44. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
45. Immunohistochemical prediction of radiation response and local control in radiation therapy for cervical cancer
46. Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB- 1 and PC10 labeling indices